Compare · PODD vs WST
PODD vs WST
Side-by-side comparison of Insulet Corporation (PODD) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PODD and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $26.17B, about 2.7x PODD ($9.58B).
- Over the past year, PODD is down 55.7% and WST is up 45.2% - WST leads by 100.8 points.
- PODD has been more active in the news (7 items in the past 4 weeks vs 4 for WST).
- PODD has more recent analyst coverage (25 ratings vs 20 for WST).
- Company
- Insulet Corporation
- West Pharmaceutical Services Inc.
- Price
- $138.53+3.43%
- $382.07+1.93%
- Market cap
- $9.58B
- $26.17B
- 1M return
- -1.44%
- +5.43%
- 1Y return
- -55.66%
- +45.17%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 7
- 4
- Recent ratings
- 25
- 20
Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest PODD
- Insulet Announces Omnipod Discover Now Available in U.S.
- Barclays initiated coverage on Insulet with a new price target
- SEC Form 4 filed by Insulet Corporation
- Director Mazelsky Jonathan Jay was granted 141 shares, increasing direct ownership by 10% to 1,496 units (SEC Form 4)
- Director Huffines Robert Luther was granted 178 shares, increasing direct ownership by 7% to 2,627 units (SEC Form 4)
- Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
- Insulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
- Insulet Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Insulet Corporation filed SEC Form 8-K: Leadership Update
Latest WST
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Pharm upgraded by Morgan Stanley with a new price target
- Sr. VP & Chief HR Officer Favorite Annette F exercised 7,524 shares at a strike of $89.64 and sold $2,671,260 worth of shares (7,524 units at $355.03) (SEC Form 4)
- Sr. VP & Chief HR Officer Favorite Annette F exercised 8,135 shares at a strike of $85.37 and sold $2,772,489 worth of shares (8,135 units at $340.81) (SEC Form 4)
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences